International Journal of New Chemistry
ISC, DOAJ, CAS, Google Scholar......

A New Chemical-based Survey on Newly-developed MAPK Inhibitors as Cancer Chemopreventive Agents

Document Type : Review

Authors

Leila Bayat 1
Alireza Moghaddasi 1
Hosna Zarei 2
Ayda Jenabian 2
Sophia Pirbabaee 2
Maryam Bayanati 3
Mohammad Mahboubi-Rabbani 1

1 Department of Medicinal Chemistry, School of Pharmacy and Pharmaceutical Sciences, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

2 Department of Pharmaceutical Chemistry, School of Pharmacy and Pharmaceutical Sciences, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

3 Department of Food Technology Research, National Nutrition, and Food Technology Research Institute/Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

10.22034/ijnc.2025.721330
Abstract
The mitogen-activated protein kinase (MAPK) signaling pathway plays a crucial role in cell proliferation, differentiation, and survival. Dysregulation of MAPK signaling is implicated in various diseases, including cancer, neurodegeneration, and inflammatory disorders. MAPK inhibitors, targeting kinases such as ERK, JNK, and p38, have been developed as therapeutic agents. Recent advances in the field include ATP-competitive inhibitors, allosteric inhibitors, and dual kinase inhibitors, offering improved selectivity and efficacy. This review discusses the latest developments in MAPK inhibitors, focusing on their chemical structures, mechanisms of action, and therapeutic applications.

Keywords

MAPK Inhibitors
Cancer Chemoprevention
Signal Transduction Pathways
Small Molecule Therapeutics
Targeted Cancer Therapy
Subjects
1          Davies, H. et al. Nature 417, 949-954 (2002).
2          Xue, Y. et al. Nature medicine 23, 929-937 (2017).
3          Zheng, S.-T. et al. Molecular biology reports 38, 865-872 (2011).
4          Tam, S. Y. & Law, H. K.-W. Cancers 13, 2196 (2021).
5          Rovida, E. & Tusa, I.  Vol. 23   5702 (MDPI, 2022).
6          Naderi, J., Hung, M. & Pandey, S. Apoptosis 8, 91-100 (2003).
7          Zhang, J., Yang, P. L. & Gray, N. S. Nature reviews cancer 9, 28-39 (2009).
8          Choi, J. H., Ji, Y. G., Ko, J. J., Cho, H. J. & Lee, D. H. Pancreas 47, 643-651 (2018).
9          Hilger, R., Scheulen, M. & Strumberg, D. Oncology Research and Treatment 25, 511-518 (2002).
10        Yang, S. & Liu, G. Oncology letters 13, 1041-1047 (2017).
11        Haeusgen, W., Herdegen, T. & Waetzig, V. European journal of cell biology 90, 536-544 (2011).
12        Sundarrajan, M., Boyle, D. L., Chabaud‐Riou, M., Hammaker, D. & Firestein, G. S. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology 48, 2450-2460 (2003).
13        Zarubin, T. & Han, J. Cell research 15, 11-18 (2005).
14        Obata, T., Brown, G. E. & Yaffe, M. B. Critical care medicine 28, N67-N77 (2000).
15        Fu, L., Chen, S., He, G., Chen, Y. & Liu, B. Journal of Medicinal Chemistry 65, 13561-13573 (2022).
16        Subbiah, V. et al. Cancer Research 82, CT160-CT160 (2022).
17        Larkin, J. et al. New England Journal of Medicine 371, 1867-1876 (2014).
18        Pathria, G., Garg, B., Garg, K., Wagner, C. & Wagner, S.
19        Yong, H.-Y., Koh, M.-S. & Moon, A. Expert opinion on investigational drugs 18, 1893-1905 (2009).
20        Kuma, Y. et al. Journal of Biological Chemistry 280, 19472-19479 (2005).
21        Carpentier, I. et al. FEBS letters 425, 195-198 (1998).
22        Shamsnia, H. S. et al. Inflammopharmacology 31, 2201-2212 (2023).
23        Santos, M. A. et al. Archives of gerontology and geriatrics 92, 104266 (2021).
International Journal of New Chemistry
Volume 11, Issue 4
Winter 2024
Pages 543-552

Home

Reviewers